In particular, in the presence of M694V homozygotes, patients with elevated CRP and a PIV ≥ 518.1 cut-off in the attack-free period should be closely monitored for the risk of amyloidosis and moderate-to-severe disease. The gene discussed is CRP; the disease is amyloidosis.